P-glycoprotein: from genomics to mechanism

1,066 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways (2011, background): “Members of this transmembrane superfamily act as unidirectional cellular pumps and have been linked with multidrug resistance”
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. (2004, background): “classic enzyme-substrate/lock-and-key manner and therefore standard Menten-Michaelis kinetics cannot be readily applied to their activity (Begley et al., 2000; Martin et al., 2000; Sauna & Ambudkar, 2001; Ambudkar et al., 2003; Begley, 2003; Chang, 2003; Litman et al., 2003; Begley 2004a, 2004b).”
Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. (2006, background): “quires the hydrolysis of a second ATP (13).”
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. (2005, background): “However, whether the molecule functions as a chemotherapeutic drug efflux transporter in malignant melanoma cells and hence as a mediator of chemoresistance to specific efflux substrates, a function suggested by its close structural homology with the known human MDR transporter paralog ABCB1 P-gp, h”
Diagnosing and exploiting cancer's addiction to blocks in apoptosis (2008, background): “Indeed, p-glycoprotein-type multi-drug resistance pumps might account for a subset of pan-resistance observe”